Royalty Pharma Rises Portfolio Receipts Guidance to $3.4-$3.5B
The company reported strong Q2 2026 results and raised its full-year Portfolio Receipts guidance range. Additionally, it announced capital deployment of $1.1 billion and pipeline updates including FDA and EC approvals for several partnered therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day